PAB (ASX) Short term future of PAB

Originally posted by mattyedw: ↑

Just a mere 6 weeks ago when a few long termers decided to exit to look for gains elsewhere the believers stood firm knowing news was imminenent(could of been bad news but if you followed the Dr's confidance bad news was a very low percentage)
The price 6 weeks ago was 2c.....

From then news has filtered through and below just a few pointers in the last few weeks

New Mechanism By Which PAT-DX1 May Reduce Cancer Metastasis
"Patrys Chief Executive Officer and Managing Director, Dr. James Campbell said: “This is an unexpected and important discovery for Patrys, offering mechanistic rationale to the previouslydescribed ability of PAT-DX1 to reduce cancer spread by metastasis, and opening the door to broader uses of deoxymabs in non-cancer indications, particularly chronic inflammatory conditions that are driven by NET formation. The discovery has been protected by patent application, and opens new areas for business development to Patrys.”

Significant funding to support deoxymab brain cancer research
"Patrys Chief Executive Officer and Managing Director, Dr. James Campbell said: “This is one of our most exciting collaborations to date. Professor Johns and his team are leaders in brain cancer translational research in Australia and have numerous international connections."

PAT-DX1 Engineering Run Successfully Completed
Patrys Chief Executive Officer and Managing Director, Dr. James Campbell said: “This is an outstanding result, and a tribute to the close working relationship between Patrys and our CDMO. The commercial-scale manufacture of antibodies is a complex, multi-dimensional process. The efforts made to understand and remediate the issues with the first engineering run have been both extensive and exhaustive. We are delighted that this has delivered such a successful outcome, both addressing the issue with the original purification process and improving the overall yield. We are now in a position to proceed with our plan to initiate the final GLP toxicology studies by the end of the year, to support our target of initiating a phase 1 clinical study of PAT-DX1 in H2 CY2023.”

Retirement of Non-Executive Chair
Patrys Chief Executive Officer and Managing Director, Dr. James Campbell said: “John has made a sustained and significant contribution to Patrys since his appointment as Chair in May 2007. Patrys has transformed considerably under John’s stewardship, and he leaves the Company in a strong position and with a clear trajectory to becoming a clinical-stage company

The above is an opening that i am sure has been a strategic course of action to bring some one in that has the connections to maximize PAB's IP and help turn it into ground breaking deals.

And from Yesterdays left field play

PAT-DX1 in Combination with Radiation Therapy Significantly Improves Survival in Animal Model of Brain Cancer
Patrys Chief Executive Officer and Managing Director, Dr. James Campbell said: “This is a very exciting result, showing a robust benefit from combining PAT-DX1 with standard of care radiation therapy in high grade glioma, one of the most difficult-to-treat cancers. This, and additional studies funded under the auspices of Cure Brain Foundations’ Clinical Accelerator program, of which our collaborator Professor Johns was the inaugural recipient, will guide us towards optimised therapeutic regimes and timing schedules as we progress PAT-DX1 into the clinic.

THIS BIT I WANTED TO STAND ALONE
Having successfully completed our engineering run for PAT-DX1 recently we are well positioned to advance towards the clinic, and excited by the potential of this novel and exciting agent.”

Completed the eng. run and the chairman retiring with this being succesful tells me that the eng.run now has been completly ticked..
AND...They are excited by the POTENTIAL of this novel agent.......

Thats not it all theres more but on average thats 1 positive/price senitive Ann every 2 weeks and the SP now is 30% higher than from when the less confidence sold out....

All the above and other Ann's elude imho to have massive potentials and PAB again imho have far too much to handle on their own....

Together with the new VP and what ever calibre the Dr brings into chair imho is setting up PAB nicely to broker some amazing partnerships/jv's/licencing contracts

We have the support and backing of one of the leading Cancer specialists world wide that is doing trials with us(would he waste his time on a dud drug??????????)

The future looks very very bright and the Dr is starting to solidify and bring value back to the share holders with all this tremendous news..
The Dr knows he has to build the SP from here and he has to smash a few more good Ann's to break to new highs so the big boys cannot sell it down on small volume.
He also knows if he wants deals/good money for partnerships ect then the base of negociations have to start well North of where we are now....

I have never invested in a more competent BoD/CEO and the riches he will bring to the Share holders and indeed the cancer sufferers in the not to distant future is just mind boggling....

Good luck ye old faithfull as the ride of a lifetime is just getting started..

Expand

Matt

Couldn't agree more.

And lets never lose sight that as investors, our rewards for commitment, in the long term will be inexplicably linked to a medical outcome that will benefit many and hopefully cure someone. There was some silly comment yesterday about the statistical outcome of the mice with only a few surviving long term. Its not lost on me that the sample may be considered to small, but if those mice that survived was my Mom or daughter, that would be an incredible result.

Good luck to all.

No.	Vol.	Price($)
2	494316	0.8¢

No.

Vol.

Price($)

494316

0.8¢

Price($)	Vol.	No.
0.9¢	1426680	2

Price($)

Vol.

No.

0.9¢

1426680

No.	Vol.	Price($)
2	494316	0.008
20	5753441	0.007
9	2237680	0.006
8	3155992	0.005
5	4324000	0.004

No.

Vol.

Price($)

494316

0.008

5753441

0.007

2237680

0.006

3155992

0.005

4324000

0.004

Price($)	Vol.	No.
0.009	1426680	2
0.010	1400000	2
0.011	1610000	5
0.012	372407	3
0.013	990000	2

Price($)

Vol.

No.

0.009

1426680

0.010

1400000

0.011

1610000

0.012

372407

0.013

990000

(20min delay)
Last 0.8¢		Change -0.001(11.1%)		Mkt cap ! $16.46M

Open	High	Low	Value	Volume
0.8¢	0.8¢	0.8¢	$1.28K	160K

Short term future of PAB, page-2

Featured News

Prominence impresses the market with uranium grading 5,269ppm in Kazakhstan

Tamboran is listing on the NYSE, and Wall Street is paying attention

Gold grading beyond 65g/t at Hillgrove gets Larvotto shares airborne

Alara Resources (ASX:AUQ) is driving Oman into a renewable renaissance with accelerating copper production

Maiden drilling at West Arunta hints at major IOCG system for Rincon

Buyers (Bids)

Sellers (Offers)

Featured News

Short term future of PAB, page-2

Featured News

Top Stories

Prominence impresses the market with uranium grading 5,269ppm in Kazakhstan

Tamboran is listing on the NYSE, and Wall Street is paying attention

Gold grading beyond 65g/t at Hillgrove gets Larvotto shares airborne

Alara Resources (ASX:AUQ) is driving Oman into a renewable renaissance with accelerating copper production

Maiden drilling at West Arunta hints at major IOCG system for Rincon

Buyers (Bids)

Sellers (Offers)

Featured News